Funding for this research was provided by:
Eli Lilly and Company (EVA-27031)
Received: 21 November 2022
Accepted: 10 July 2023
First Online: 6 September 2023
: All study methods and materials were approved by an independent review board (Ethical and Independent Review Services [E&I], E&I study numbers 20103 and 21001), and participants provided written informed consent prior to completing any study procedures.
: This qualitative study was funded by Eli Lilly and Company. Authors LSM and KDS are employed by Evidera, a company that received funding from Lilly for time spent on this research. Authors HP and KSB are employed by and own stock in Eli Lilly.